Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.89 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229157 | 0.94 | MEN1 (1.00) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL11758762 | 0.92 | MEN1 (0.94) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL21765846 | 0.92 | MEN1 (0.94) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL9259257 | 0.92 | MEN1 (0.94) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL13024411 | 0.90 | MEN1 (0.73) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL30941449 | 0.90 | MEN1 (0.73) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL14439572 | 0.90 | MEN1 (0.81) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL15934269 | 0.90 | MEN1 (0.73) | MEN1KMT2ARECQLCASP2ALDH1A1 | |
| SCHEMBL277343 | 0.89 | — | — | |
| SCHEMBL13492955 | 0.88 | MEN1 (0.70) | MEN1KMT2ARECQLCASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0192299-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE AND 2-ALKYLPYRIMIDINE | STAMICARBON B.V. (NL) | 1990-08-29 | — | — | EP | claimed |
| US-4775755-A | DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE | STAMICARBON B. V. (NL) | 1988-10-04 | — | — | US | claimed |
| EP-0192299-A1 | Process for the preparation of pyrimidine and 2-alkylpyrimidine | STAMICARBON B.V. (NL) | 1986-08-27 | — | — | EP | claimed |
| EP-4212180-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | The Scripps Research Institute (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20210102185-A1 | Protein Macrocyclization | STICHTING VU (NL) | 2021-04-08 | — | — | US | disclosed |
| US-9145514-B2 | Temperature management indicator and structure having the same attached | NICHIYU GIKEN KOGYO CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9074264-B2 | Method for recovering precious metal from solution containing precious metal ions, extracting agent or adsorbent used therefor, and back-extracting agent or desorbent | TOSOH CORPORATION (JP) | 2015-07-07 | — | — | US | disclosed |
| WO-2015095406-A1 | MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20130281726-A1 | METHOD FOR RECOVERING PRECIOUS METAL FROM SOLUTION CONTAINING PRECIOUS METAL IONS, EXTRACTING AGENT OR ADSORBENT USED THEREFOR, AND BACK-EXTRACTING AGENT OR DESORBENT | TOSOH CORPORATION (JP) | 2013-10-24 | — | — | US | disclosed |
| EP-2554961-A1 | TEMPERATURE MANAGEMENT INDICATOR AND STRUCTURE HAVING THE SAME ATTACHED | Nichiyu Giken Kogyo Co. Ltd. (JP) | 2013-02-06 | — | — | EP | disclosed |
| US-20130014690-A1 | TEMPERATURE MANAGEMENT INDICATOR AND STRUCTURE HAVING THE SAME ATTACHED | NICHIYU GIKEN KOGYO CO., LTD. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20120164039-A1 | PALLADIUM ION ADSORBENT AND METHODS FOR SEPARATING AND RECOVERING PALLADIUM USING IT | TOSOH CORPORATION (JP) | 2012-06-28 | — | — | US | disclosed |
| EP-0192299-B1 | PROCESS FOR THE PREPARATION OF PYRIMIDINE AND 2-ALKYLPYRIMIDINE | STAMICARBON B.V. (NL) | 1990-08-29 | — | — | EP | disclosed |
| US-4775755-A | DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE | STAMICARBON B. V. (NL) | 1988-10-04 | — | — | US | disclosed |
| US-4775755-A | DIAMINOPROPANE OR TETRAHYDROPYRIMIDINE REACTED WITH FORMAMIDE | STAMICARBON B. V. (NL) | 1988-10-04 | — | — | US | disclosed |
| EP-0192299-A1 | Process for the preparation of pyrimidine and 2-alkylpyrimidine | STAMICARBON B.V. (NL) | 1986-08-27 | — | — | EP | disclosed |
| EP-0192299-A1 | Process for the preparation of pyrimidine and 2-alkylpyrimidine | STAMICARBON B.V. (NL) | 1986-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120164039-A1 | PALLADIUM ION ADSORBENT AND METHODS FOR SEPARATING AND RECOVERING PALLADIUM USING IT | PDCD10, PARK7, CCR10 | MEN1 1969/4885KMT2A 643/4885RECQL 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.